Drug Development Pipeline
Back to the Drug Development Pipeline
LAU-7b is an oral compound. It is a form of the retinoid fenretinide. Retinoids are a group of compounds related to vitamin A. Fenretinide may help reduce the inflammatory response in the lungs of people with CF.
A phase 2 study to test the safety and effectiveness of LAU-7b in people with CF is underway.
This program is sponsored by Laurent Pharmaceuticals. It is being conducted within the Therapeutics Development Network.
Recent LAU-7b Studies
Closed to Enrollment
Phase 2 study of LAU-7b in adults with CF (APPLAUD) (Laurent LAU-14-01)
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.Learn More